Back to Search Start Over

Minor histocompatibility antigens as targets for T-cell immunotherapy

Authors :
Dmitrii Romaniuk
V. G. Savchenko
Artem Pilunov
Grigory A. Efimov
Source :
Russian journal of hematology and transfusiology. 66:322-345
Publication Year :
2021
Publisher :
National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation, 2021.

Abstract

Introduction. Minor histocompatibility antigens (MiHAs) — polymorphic peptides presented in HLA molecules that are products of genes containing nonsynonymous single nucleotide polymorphisms. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the immune response directed to MiHA can result both in graft-versus-host and graft-versus-tumor responses.Some MiHAs are promising and safe targets for T-cell immunotherapy of leukemia relapse after allo-HSCT.Aim — to analyze the literature describing the immune response to various MiHAs, as well as clinical trials using MiHAs as targets of immunotherapy.Main findings. MiHAs represent promising targets for the prevention or therapy of leukemia relapse after allo-HSCT due to their advantages over tumor-associated antigens and neoantigens. To be suitable for immunotherapy, MiHA must satisfy several parameters: 1) be presented by a common HLA allele, 2) have an optimal frequency of polymorphism-encoding allele, 3) be encoded by a gene that is predominantly expressed in hematopoietic tissue. This drastically limits the number of applicable targets and makes the discovery of new MiHAs highly relevant.

Details

ISSN :
24113042 and 02345730
Volume :
66
Database :
OpenAIRE
Journal :
Russian journal of hematology and transfusiology
Accession number :
edsair.doi...........00720d1e98d498af43a4feef29a50e01
Full Text :
https://doi.org/10.35754/0234-5730-2021-66-3-322-345